Trimeris, Novartis, Roche deal

Trimeris will no longer be responsible for $18.7 million owed to Roche related to marketing expenses for Fuzeon

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE